Condition (MeSH)
Neoplasm Recurrence, Local
ClinicalTrials.gov lists 42 trials for Neoplasm Recurrence, Local or a narrower condition beneath it. Bioniche Life Sciences Inc. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
42 of the 42 trials are tagged with Neoplasm Recurrence, Local itself; the rest are tagged with a narrower condition beneath it.
When did Neoplasm Recurrence, Local trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 5 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 1 |
| 2020 | 2 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 3 |
Showing 10 of 24 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 21 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neoplasm Recurrence, Local trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Phase 2/3 | 2 |
| Phase 3 | 9 |
| Not applicable | 12 |
| Observational | 12 |
How many Neoplasm Recurrence, Local trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 11 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 19 |
| Terminated | 2 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neoplasm Recurrence, Local trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bioniche Life Sciences Inc. | 2 |
| Andarix Pharmaceuticals | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Radiotherapy | 3 |
| Fluorouracile | 2 |
| Lumbar puncture | 1 |
| Oxaliplatin, gemcitabine, cisplatin, lipiodol | 1 |
| General anesthesia alone | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Neoplasm Recurrence, Local trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neoplasm malignant | 22 | 1 |
| Neutropenia | 12 | 1 |
| Anaemia | 9 | 1 |
| Procedural pain | 8 | 1 |
| Pyrexia | 6 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Neoplasm Recurrence, Local? (7,804)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort. | Cancer | 2026 | Yes |
| A Randomized Trial of Endoscopic Submucosal Dissection vs Transanal Minimally Invasive Surgery in Early Rectal Neoplasms: DSETAMIS-2018 Study. | Gastroenterology | 2026 | Yes |
| [<sup>177</sup>Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2026 | Yes |
| Safety and Efficacy Findings From a Phase Ib/II Study of ASP-1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. | Head & neck | 2026 | Yes |
| Nivolumab for Resected Stage III or IV Melanoma at 9 Years. | The New England journal of medicine | 2026 | Yes |
Showing 5 of 7,804 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.